← Back to Search

Long-term Safety of 177Lu-IPN01072 for Neuroendocrine Cancer

N/A
Waitlist Available
Research Sponsored by Ipsen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant must have received at least one infusion of 177Lu-IPN01072 in Study OPS-C-001
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during the whole study period (approximately 5 years).
Awards & highlights
No Placebo-Only Group

Summary

This trial is to study the long-term safety of a medicine for patients who have received it in a previous study.

Who is the study for?
This study is open to individuals who have previously received at least one infusion of the drug 177Lu-satoreotide tetraxetan (also known as 177Lu-IPN01072) in a specific clinical trial. Participants must be able to give informed consent. There are no exclusion criteria for this safety surveillance.
What is being tested?
The study isn't testing a new treatment but is collecting long-term safety data on the medicine 177Lu-satoreotide tetraxetan, which participants have already been treated with in an earlier phase of research.
What are the potential side effects?
Since this trial involves data collection rather than administering drugs, it does not introduce new side effects. However, it monitors any long-term side effects from previous treatments with 177Lu-satoreotide tetraxetan.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have received at least one dose of 177Lu-IPN01072 in a specific study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the whole study period (approximately 5 years).
This trial's timeline: 3 weeks for screening, Varies for treatment, and during the whole study period (approximately 5 years). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Changes over time in laboratory tests (biochemistry)
Changes over time in laboratory tests (haematology)
Proportion of treatment-related adverse events of any grade.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Data collectionExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

IpsenLead Sponsor
351 Previous Clinical Trials
74,352 Total Patients Enrolled
34 Trials studying Neuroendocrine Tumors
2,974 Patients Enrolled for Neuroendocrine Tumors
Ipsen Medical DirectorStudy DirectorIpsen
260 Previous Clinical Trials
56,238 Total Patients Enrolled
26 Trials studying Neuroendocrine Tumors
2,265 Patients Enrolled for Neuroendocrine Tumors

Media Library

Data collection Clinical Trial Eligibility Overview. Trial Name: NCT05017662 — N/A
Neuroendocrine Tumors Research Study Groups: Data collection
Neuroendocrine Tumors Clinical Trial 2023: Data collection Highlights & Side Effects. Trial Name: NCT05017662 — N/A
Data collection 2023 Treatment Timeline for Medical Study. Trial Name: NCT05017662 — N/A
~1 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top